Achieve Life Sciences (ACHV) Other Non-Current Liabilities (2010 - 2026)
Achieve Life Sciences (ACHV) posted Other Non-Current Liabilities of $1.3 million for Q1 2026, down 18.3% on a QoQ basis from $1.6 million in Q4 2025, and up 2.58% year-over-year from $1.2 million in Q1 2025.
Achieve Life Sciences (ACHV) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Achieve Life Sciences' Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 2.58% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 2.58% YoY) and the FY2025 annual result came in at $1.6 million, up 35.51% from the prior year.
- Other Non-Current Liabilities was $1.3 million for Q1 2026 at Achieve Life Sciences, down from $1.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.6 million in Q4 2025 and bottomed at $528000.0 in Q4 2023.
- A 4-year average of $957750.0 and a median of $924000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities jumped 117.61% — and 2026, when it grew 2.58%.
- Achieve Life Sciences' Other Non-Current Liabilities stood at $528000.0 in 2023, then surged by 117.61% to $1.1 million in 2024, then jumped by 35.51% to $1.6 million in 2025, then declined by 18.3% to $1.3 million in 2026.
- Business Quant data shows ACHV's Other Non-Current Liabilities at $1.3 million in Q1 2026, $1.6 million in Q4 2025, and $1.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Achieve Life Sciences | 2.54 Mn | 2.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 1.15 Mn |
| Sep 30, 2024 | 699,000.00 |
| Jun 30, 2024 | 637,000.00 |
| Mar 31, 2024 | 580,000.00 |
| Dec 31, 2023 | 528,000.00 |
| Sep 30, 2017 | 3,000.00 |
| Jun 30, 2017 | 114,000.00 |
| Mar 31, 2017 | 180,000.00 |
| Dec 31, 2016 | 232,000.00 |
| Sep 30, 2016 | 350,000.00 |
| Jun 30, 2016 | 971,000.00 |
| Mar 31, 2016 | 438,000.00 |
| Dec 31, 2015 | 1.11 Mn |
| Sep 30, 2015 | 2.84 Mn |
| Jun 30, 2015 | 2.97 Mn |
| Mar 31, 2015 | 2.54 Mn |
| Dec 31, 2014 | 3.00 Mn |